Fostamatinib – IgAN


Oral SYK Inhibitor for IgA Nephropathy:

  • IgA Nephropathy (IgAN) is a chronic autoimmune disease associated with inflammation in the kidneys that diminishes their ability to filter blood.
  • IgAN is the most common primary glomerular disease. There are an estimated 82,500 - 165,000 cases in the US, with a higher prevalence in Asia.
  • Outside of angiotensin blockade (primarily for blood-pressure control), there are no approved therapies for IgAN.
  • Rigel's fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor. Pre-clinical data show that fostamatinib in IgAN, may decrease SYK activation in the kidney, resulting in the reversal of the inflammation in the glomeruli and improvement in kidney function.
  • Rigel announced preliminary results of the first cohort (100mg BID, n=26; placebo n=12) of a Phase 2 study of fostamatinib in IgAN in January 2017. Rigel announced topline results for the complete Phase 2 proof-of-concept trial, including the higher dose of fostamatinib (150mg BID), in April 2018.

Clinical Trials:

Phase 2 - IgA Nephropathy

MOA Animation: